AlphaCentric Advisors’s AnaptysBio ANAB Stock Holding History

AlphaCentric Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,000	Closed	-$86K	–	211
2020 Q4	$86K	Buy	+4,000	New	+$97.1K	0.04%	151

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AlphaCentric Advisors's ANAB Position: Q1 2021 in Review

AlphaCentric Advisors sold out of AnaptysBio (ANAB) in Q1 2021, closing a stake of 4,000 shares — an estimated $86K sold.

AlphaCentric Advisors first reported a position in ANAB in Q4 2020 and held it in 1 quarter. The position peaked at $86K in Q4 2020. 122 funds tracked by Wall St. Rank hold ANAB as of Q1 2021.

AlphaCentric Advisors reported no remaining AnaptysBio position as of Q1 2021 after selling out during the quarter.
AlphaCentric Advisors sold 4,000 AnaptysBio shares in Q1 2021, an estimated $86K.
AlphaCentric Advisors first reported a position in AnaptysBio in Q4 2020 and held it in 1 quarter.
AlphaCentric Advisors's AnaptysBio position peaked at $86K in Q4 2020.
122 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2021.

Based on AlphaCentric Advisors's 13F filing for Q1 2021, filed 9 Mar 2022.